Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24)...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Rocco, Maja, Forleo-Neto, Eduardo, Pignolo, Robert J., Keen, Richard, Orcel, Philippe, Funck-Brentano, Thomas, Roux, Christian, Kolta, Sami, Madeo, Annalisa, Bubbear, Judith S., Tabarkiewicz, Jacek, Szczepanek, Małgorzata, Bachiller-Corral, Javier, Cheung, Angela M., Dahir, Kathryn M., Botman, Esmée, Raijmakers, Pieter G., Al Mukaddam, Mona, Tile, Lianne, Portal-Celhay, Cynthia, Sarkar, Neena, Hou, Peijie, Musser, Bret J., Boyapati, Anita, Mohammadi, Kusha, Mellis, Scott J., Rankin, Andrew J., Economides, Aris N., Trotter, Dinko Gonzalez, Herman, Gary A., O’Meara, Sarah J., DelGizzi, Richard, Weinreich, David M., Yancopoulos, George D., Eekhoff, E. Marelise W., Kaplan, Frederick S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579054/
https://www.ncbi.nlm.nih.gov/pubmed/37770652
http://dx.doi.org/10.1038/s41591-023-02561-8

Ejemplares similares

Ejemplares similares